The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Clinical Implications of Basic Research
PreviousPrevious
Volume 349:2265-2266 December 4, 2003 Number 23
NextNext

Forestalling Fibrosis
Julie R. Ingelfinger, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
The concept that certain medications may protect the injured kidney from the progressive fibrosis that leads to end-stage renal disease has gained support since initial reports that interfering with angiotensin II and its effects slows advancing kidney failure.1 Angiotensin-converting–enzyme inhibitors and angiotensin-receptor blockers have become widely prescribed and appear to forestall renal failure in diabetic nephropathy and other renal diseases. Other drug classes such as antioxidants seem to confer some protection, and experimental approaches to find molecules that interfere with the effects of profibrotic molecules such as transforming growth factor {beta} (TGF-{beta}) hold some promise. However, none of these actual . . . [Full Text of this Article]


This article has been cited by other articles:


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.